New cancer combo targets immune system in early safety trial
NCT ID NCT04215978
Summary
This early-stage study tested the safety and best dose of a new two-drug immunotherapy combination (BGB-A445 plus tislelizumab) in 204 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how much of the drugs patients could tolerate and to check for side effects. Researchers also looked for early signs that the treatment could shrink tumors in cancers like lung, head and neck, and nasopharyngeal carcinoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Zhongshan Hospital Of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Blacktown Cancer And Haematology Centre
Blacktown, New South Wales, 2148, Australia
-
California Cancer Associates for Research & Excellence (cCARE)
San Diego, California, 92127, United States
-
Cha Bundang Medical Center, Cha University
Gyeonggido, Gyeonggi-do, 13496, South Korea
-
Changhua Christian Hospital
Changhua, NAP, 500-06, Taiwan
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
King Chulalongkorn Memorial Hospital (Chulalongkorn University)
Bangkok, 10330, Thailand
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Linyi Cancer Hospital
Linyi, Shandong, 276001, China
-
Monash Health
Clayton, Victoria, 3168, Australia
-
National Cancer Center (NCC)
Goyang-si, Gyeonggi-do, 10408, South Korea
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Pindara Private Hospital
Benowa, Queensland, 4217, Australia
-
Princess Alexandra Hospital
Brisbane, Queensland, 4102, Australia
-
Ramathibodi Hospital Mahidol University
Bangkok, 10400, Thailand
-
Sarawak General Hospital
Kuching, 93586, Malaysia
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, Seoul Teugbyeolsi, 03722, South Korea
-
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
-
Srinagarind Hospital (Khon Kaen University)
Muang, 40002, Thailand
-
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, 16247, South Korea
-
The Second Xiangya Hospital Of Central South University
Changsha, Hunan, 410011, China
-
UPMC Hillman Cancer Center (Univ Of Pittsburgh)
Pittsburgh, Pennsylvania, 15232, United States
-
Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology
Wuhan, Hubei, 430022, China
-
University of Malaya Medical Centre
Kuala Lumpur, 50603, Malaysia
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.